AI atlas reveals hidden whole-body-damage caused by obesity
Peer-Reviewed Publication
Updates every hour. Last Updated: 30-Oct-2026 09:17 ET (30-Oct-2026 13:17 GMT/UTC)
Researchers at Helmholtz Munich, the Ludwig Maximilians University Munich (LMU) and collaborating institutions have developed an artificial intelligence (AI) framework that maps disease-related changes throughout the entire mouse body at cellular resolution. Using the new platform, called MouseMapper, the researchers uncovered widespread inflammation and previously unrecognized damage to facial sensory nerves caused by obesity. Importantly, they also identified corresponding molecular signatures in human tissue, suggesting that key features of obesity-associated nerve damage are conserved across species. The findings are published today in the journal Nature.
Once only achievable in the far-fetched imaginations of science fiction writers, 3D printing has gone mainstream. Relatively inexpensive machines allow individuals to design and print everything from board games and desk accessories to replacement parts for household appliances and more. One of the biggest selling points is the ability to recycle a printed piece into something new, offering a potential pathway to more sustainable living. However, the highest quality 3D printing used to create extremely precise structures at the submicron scale — a method called stereolithography — uses process that involves photocuring resin by exposing the material to ultraviolet (UV) light. This irreversibly chemically changes the resin, making it impossible to recycle.
A new AI tool called Empirical Research Assistance (ERA) can automatically write high-performance scientific software and could significantly accelerate scientific discovery across many domains.
A University of Florida engineering professor says commercially available tools used to detect AI-generated text in scientific literature are ineffective.
Three faculty researchers from The University of Texas at San Antonio were celebrated with the inaugural Texas Innovation Award, a new statewide award recognizing leadership in translating academic research into real-world impact.
A phase 2 clinical trial showed burosumab, a targeted antibody therapy, safely restored phosphate balance in children and adults with fibrous dysplasia, a rare bone disorder associated with fractures and deformities. The therapy reduced abnormal bone turnover markers and improved mobility in severely affected children, including independent walking after full-time wheelchair use. The findings suggest that inhibition of fibroblast growth factor-23 may help reduce disability and improve physical function in patients with phosphate-wasting skeletal disease.